Statins and biomarkers of inflammation

被引：78
作者：
Devaraj S. [1 ]
Rogers J. [1 ]
Jialal I. [1 ]
机构：
[1] VA Northern California Health System, Laboratory for Atherosclerosis and Metabolic Research, Universiy of California Davis Medical Center, Sacramento, CA 95817
来源：
Current Atherosclerosis Reports | 2007年 / 9卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Statin; Simvastatin; Atorvastatin; Pravastatin; Lovastatin;
D O I：
10.1007/BF02693938
中图分类号：
学科分类号：
摘要：
Clinical and epidemiologic studies convincingly demonstrate that increased levels of low-density lipoprotein cholesterol promote premature atherosclerosis. Several large clinical trials have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease cardiovascular events. The beneficial effects of statins may extend to mechanisms beyond cholesterol reduction. Evidence for the pleiotropic effects of statins is provided by recent clinical trials in which the benefit of statin drugs is manifest early in the course of lipid-lowering therapy, well before plaque regression could occur. Inflammation is pivotal in all stages of atherosclerosis, and C-reactive protein (CRP), the prototypic marker of inflammation, has emerged as a cardiovascular risk marker. Statins reduce CRP levels, and this reduction in most studies does not correlate to reduction in cholesterol. In addition, statins have beneficial effects on endothelial function, monocytemacrophages, and platelets. In this review we discuss the role of inflammation in atherosclerosis, the role of CRP as a risk marker, the clinical evidence implicating the anti-inflammatory effects of statins, and the cellular and molecular basis underlying the anti-inflammatory effects of statins. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：33 / 41
页数：8
相关论文
共 71 条
  • [1] Gordon T., Kannel W.B., Premature mortality from coronary heart disease: The Framingham Study, JAMA, 215, pp. 1617-1625, (1971)
  • [2] Iso H., Jacobs Jr. D.R., Wentworth D., Et al., Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial, N Engl J Med, 320, pp. 904-910, (1989)
  • [3] Pedersen T.R., Kjekshus J., Berg K., Et al., Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, pp. 1383-1389, (1994)
  • [4] Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group, N Engl J Med, 339, pp. 1349-1357, (1988)
  • [5] Sacks F.M., Pfeffer M.A., Moye L.A., Et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, pp. 1001-1009, (1996)
  • [6] Shepherd J., Cobbe S.M., Ford I., Et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group, N Engl J Med, 333, pp. 1301-1307, (1995)
  • [7] Packard C.J., Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS), Circulation, 97, pp. 1440-1445, (1998)
  • [8] Ridker P.M., Rifai N., Pfefffer M.A., Long-term effects of pravastatin on plasma concentration of C-reactive protein, Circulation, 100, pp. 230-235, (1999)
  • [9] Kinlay S., Schwartz G.G., Olsson A.G., Et al., High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study, Circulation, 108, pp. 1560-1566, (2003)
  • [10] Ridker P.M., Cannon C.P., Morrow D., Et al., C-reactive protein levels and outcomes after statin therapy, N Engl J Med, 352, pp. 20-28, (2005)
12345678